SHANGHAI, May 20, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Best CFO", "Best Company Board", "Best IR Program", "Best IR Professional", and "Best ESG (Environmental, Social and Governance)" among different vote types, in the ranking of "2025 Asia (ex-Japan) Executive Team" by Extel (previously "Institutional Investor").
This is the second year that WuXi XDC has participated in the Extel ranking and won multiple awards. With its outstanding comprehensive strength, WuXi XDC achieved the "Grand Slam" in all ranking categories and in three different sectors -"All market capitalization" , "Small and Medium-sized market capitalization", and "Chinese mainland".
As a leading international financial survey publisher, Extel creates its research-supported rankings and names award recipients based on combined buy-side and sell-side surveys within the industry. The ranking and award recipients have been seen as impactful to the capital market since its debut. This year, 5,437 investment professionals from 1,167 financial service firms casted votes in core areas including accessibility of senior executives, execution of strategy, well-informed and empowered IR Team, timeliness of disclosure, corporate and board governance, and ESG performance.
Mr. Michael Xi, CFO of WuXi XDC, stated, "As a leading global CRDMO, we have been honored with multiple awards in the Extel Award for two consecutive years. This accomplishment signifies the international capital market's recognition of WuXi XDC's strategic positioning, corporate governance and social returns, and value creation capabilities. This award serves as both recognition and a responsibility. WuXi XDC will continue to foster a rewarding cycle of business growth and shareholder returns by maintaining deep market insights into bioconjugate development and enhancing global operational efficiency".
WuXi XDC was listed on the Hong Kong Stock Exchange Main Board in November 2023, raising over HKD 4 billion（post green-shoe）and was named "Best IPO" by IFR Asia that year. In March 2024, the company was included in the stock list of Hong Kong Stock Connect. As of Today, WuXi XDC has been officially covered by over 30 sell-side analysts/firms, including major domestic and global sell-side institutions and the holding percentage of Hong Kong Stock Connect in WuXi XDC's total issued shares has climbed to over 13%. The company has been included as a component stock in multiple indices, such as the Hang Seng Composite Index (HSCI), the Hang Seng Hong Kong Listed Biotechnology Index (HSHKBIO), the Hang Seng Healthcare Index (HSHCI), the Hang Seng Hong Kong US Biotechnology Index (HSUSB), and the FTSE All-Cap, etc. In the realm of capital market accolades, the company has been the recipient of prestigious industry honors including "Top Investor-Picked Companies", "Most Valuable Pharmaceutical and Healthcare Company", "Most Promising Hong Kong-listed Pharma Company", "A Rating in the Wind ESG Rankings" and "Top 20 Pharmaceutical Listed Companies in ESG Competitiveness 2024".
In 2024, WuXi XDC has continued to reinforce its leading position in the ADC and bioconjugates CRDMO field, with revenue increased by 90.8% YoY to RMB 4,052 million, and net profit surged by 277.2% YoY to RMB 1,070 million. As of December 31, 2024, the company has cumulatively served nearly 500 global customers and successfully delivered over 14,000 bioconjugate molecules. The "Enable, Follow and Win the Molecule" strategy continued to drive sustained and rapid project growth. By the end of 2024, the total number of integrated CMC projects had reached 194, supporting 85 IND submissions. 13 out of top 20 global pharmaceutical companies have partnered with company for R&D and manufacturing services of ADCs and broader bioconjugates.
About WuXi XDC
WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com.
WuXi XDC Contacts
Investor: wuxixdc.ir@wuxibiologics.com
Media: wuxixdc_pr@wuxibiologics.com
BD: wuxixdc_info@wuxibiologics.com
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- On January 8, 2026, CHAGEE released its 2025 Year-End Tea Friends Review. The Review outlines the company's growth over the past year, with its store network now operating in eight countries across two continents. Annual tea sourcing volume surpassed 10,000 tons, covering six major tea categories as well as key Pu'er-producing regions, supported by partnerships with more than 100 tea factories.
Global Footprint Reaches Eight Countries; Asia-Pacific Overseas Membership Climbs 177%
The 2025 Year-End Tea Friends Review shows that CHAGEE's store network currently operates in China, Malaysia, Indonesia, the Philippines, Vietnam, Thailand, Singapore, and the United States. In April, CHAGEE completed its public listing on the NASDAQ exchange (Ticker: CHA), becoming the first freshly made tea beverage brand from China to list on a U.S. stock exchange and one of the largest food and beverage IPOs globally since 2022, according to publicly available market data.
Overseas growth has supported the expansion of CHAGEE's customer base. According to the Report, membership in Asia-Pacific overseas markets rose 177% year-on-year in 2025, with 61% of members under the age of 30. Member counts in Singapore, Thailand, Indonesia, and the Philippines increased by approximately 4-fold, 5.4-fold, 20-fold, and 11-fold, respectively. Online engagement related to CHAGEE across international social platforms increased by approximately 250% compared with the prior year. Terms like "tea", "tea culture", and "tea-inspired lifestyle" have become popular among young local consumers, positioning tea as a shared point of cultural interest among younger audiences across markets.
BO•YA JASMINE GREEN MILK TEA Gains Worldwide Popularity
As CHAGEE's global presence grows, BO•YA Jasmine Green Milk Tea continued to gain recognition across international markets. Data from Frost & Sullivan shows that sales of the beverage surpassed 1.25 billion cups between January 2022 and June 2025. The Review indicates BO•YA Jasmine Green Milk Tea ranks among the top-selling products in Indonesia, the Philippines, Vietnam, and Thailand. Preferences vary by region—for instance, consumers in Malaysia and Singapore show greater interest in Peach Oolong Milk Tea—reflecting the company's strategy of tailoring offerings to local preferences as international operations expand.
In the past year, more than 30 million customers placed single orders for two or more cups of BO•YA Jasmine Green Milk Tea, highlighting shared consumption occasions. Group orders rose notably, with orders exceeding 20 cups increasing by more than 15% and orders over 100 cups rising by more than 40% year-on-year.During the Spring Festival holiday, orders of 50–100 cups surged by as much as 259% year-on-year.
In 2025, BO•YA Jasmine Green Milk Tea received the Best Natural/Organic Beverage award at the World Beverage Innovation Awards. CHAGEE was also recognized in the Best Processing/Production Innovation category and named a finalist for several additional international innovation awards.
Annual Tea Sourcing Holds at 10,000 Tons; Modern Tea Approach Supports Supply Chain Development
Within the tea industry, CHAGEE continues to deepen partnerships with upstream producers. In 2025, the company's annual tea sourcing remained at approximately the 10,000-ton scale, with partnerships extending to more than 100 tea factories.
Product innovation further links industry capabilities with consumer preferences. Last year, CHAGEE introduced over 20 new products. Within the Fresh Milk Tea series, more than 50% of new releases featured floral or fruit elements. By applying its Fresh Brew technology system, CHAGEE has integrated contemporary extraction techniques into freshly made tea beverage preparation, bringing new flavor expressions to traditional tea leaves.
In 2025, CHAGEE also completed over 10 craftsmanship and process innovation initiatives in collaboration with tea gardens, factories, and research institutions.
The 2025 Year-End Tea Friends Review further notes that CHAGEE now operates more than 25 pet-friendly stores, has supported the construction of 23 children's playgrounds this year, opened 14 deaf-inclusive silent stores, added 219 new 24-hour locations, and opened new stores at an average rate of one every 1.7 days. Approximately 1340 stores joined CHAGEE's Night Clean Project, supporting 18,000 store partners complete end-of-day operations on schedule.
"Making Friends Through Tea" is more than a tagline—it reflects CHAGEE's ongoing approach of building lasting, respectful connections centered on shared tea experiences. Each day, CHAGEE brings people together through a cup of tea.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CHAGEE Releases "2025 Year-End Tea Friends Review": Global Stores Span 8 Countries Across 2 Continents, Annual Tea Procurement Exceeds 10,000 Tons
